ChromaDex Corp. Rebrands as Niagen Bioscience, Inc.: A New Era in Healthy Aging
Los Angeles, CA – ChromaDex Corp. (CDXC), a pioneering company in the field of NAD+ (nicotinamide adenine dinucleotide) and healthy aging, has announced its intention to rebrand as Niagen Bioscience, Inc., effective March 19, 2025. The corporate name change will coincide with a new Nasdaq trading symbol, “NAGE,” signaling a significant shift in the company’s identity and strategic focus.
The Reason Behind the Name Change
Niagen Bioscience’s decision to rebrand comes as part of a broader corporate strategy to align its name more closely with its core business and mission. As a leader in NAD+ science and healthy aging, the new name emphasizes the company’s commitment to developing and commercializing innovative solutions that harness the power of NAD+ to improve human health and longevity.
Impact on Shareholders
Existing shareholders of ChromaDex Corp. do not need to take any immediate action regarding their stock holdings. The new trading symbol, “NAGE,” will replace “CDXC” beginning March 19, 2025. Shareholders are encouraged to update their records accordingly and monitor the company’s communications for further information.
Global Implications
The rebranding of ChromaDex as Niagen Bioscience represents a significant milestone not only for the company but also for the broader NAD+ industry. This transition is expected to raise awareness of the potential benefits of NAD+ supplementation and healthy aging, potentially leading to increased investment, collaboration, and innovation in this field.
Further Developments
A follow-up announcement from Niagen Bioscience is expected to provide additional details regarding the name change and rebranding efforts, including potential updates to the company’s logo, website, and marketing materials. Stay tuned for further updates and information as they become available.
Conclusion
The rebranding of ChromaDex Corp. as Niagen Bioscience marks a new chapter in the company’s journey to revolutionize the healthy aging industry through NAD+ science. This transition not only aligns the company’s name with its core mission but also positions it for continued growth and innovation in the rapidly evolving field of NAD+ and healthy aging. Shareholders and industry observers are encouraged to stay informed about Niagen Bioscience’s progress and developments as they unfold.
- ChromaDex Corp. to rebrand as Niagen Bioscience, Inc.
- Effective March 19, 2025, the company will trade under new Nasdaq symbol, “NAGE.”
- Rebranding aligns with core business and mission in NAD+ and healthy aging.
- Impact on shareholders: no immediate action required.
- Global implications: increased awareness and potential investment in NAD+ industry.
- Further updates expected in follow-up announcement.
